Insight Molecular Diagnostics (IMDX) Net Equity Issued and Repurchased (2015 - 2026)

Insight Molecular Diagnostics has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $26.0 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 10.7% year-over-year to $26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.0 million (down 52.82% YoY) and the FY2025 annual result came in at $29.1 million, up 12.04% from the prior year.
• Net Equity Issued and Repurchased slipped to $26.0 million in Q1 2026 per IMDX's latest filing, from $29.1 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $29.1 million in Q1 2025 and troughed at -$5.0 million in Q3 2022.
• A 4-year average of $15.6 million and a median of $15.8 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2022 and 2026: Net Equity Issued and Repurchased soared 2793600.0% in 2022, then declined 10.7% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at $27.9 million in 2022, then slumped by 63.47% to $10.2 million in 2024, then soared by 185.58% to $29.1 million in 2025, then decreased by 10.7% to $26.0 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $26.0 million, $29.1 million, and $10.2 million for Q1 2026, Q1 2025, and Q4 2024 respectively.